Therapeutic effects of recombinant feline interferon-ω on feline leukemia virus (FeLV)-infected and FeLV/Feline immunodeficiency virus (FIV)-coinfected symptomatic cats

Journal of Veterinary Internal Medicine

Volumn 18, Issue 4, 2004, Pages 477-482

  De Mari, Karine ^a   Maynard, Laurence ^a   Sanquer, Annaelle ^a   Lebreux, Bernard ^a   Eun, Hyone Myong ^a  

^a Virbac SA   (France)

Author keywords

Feline leukemia; Interferon therapy; Recombinant feline interferon

Indexed keywords

RECOMBINANT INTERFERON; RECOMBINANT INTERFERON OMEGA; UNCLASSIFIED DRUG;

ARTICLE; CAT DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED DISEASE; DRUG SAFETY; ERYTHROCYTE COUNT; FELINE IMMUNODEFICIENCY VIRUS; FELINE LEUKEMIA VIRUS; FEMALE; FOLLOW UP; HEMATOCRIT; KIDNEY FAILURE; LETHARGY; LEUKOCYTE COUNT; MALE; MORTALITY; NONHUMAN; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

ANIMALS; CAT DISEASES; CATS; DRUG ADMINISTRATION SCHEDULE; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I; LEUKEMIA VIRUS, FELINE; LEUKEMIA, FELINE; LEUKOCYTE COUNT; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELINE LEUKEMIA VIRUS; FELIS CATUS;

EID: 4243120808     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<477:TEORFI>2.0.CO;2     Document Type: Article

References (26)

1. Jarrett WFH, Crawford EM, Martin WB, Davie FA. A virus-like particle associated with leukemia (lymphosarcoma). Nature 1964;202:567-569.
2. Hoover EA, Mullins JI, Quackenbush SL, Gasper PW. Experimental transmission and pathogenesis of immunodeficiency syndrome in cats. Blood 1987;70:1880-1892.
3. McClelland AJ, Hardy WD, Zuckerman EE. Prognosis of healthy feline leukemia virus infected cats. In: Hardy WD, Essex M, McClelland AJ, eds. Feline Leukemia Virus. Developments in Cancer Research. New York, NY: Elsevier Science Publishing Co; 1980:121-126.
4. Dean GA, Groshek PM, Mullins JI, Hoover EA. Hematopoietic target cells of anemogenic subgroup C versus nonanemogenic subgroup A feline leukemia virus. J Virol 1992;66:5561-5568.
5. Hartmann K, Kraft W. FeLV infection. Rev Med Vet 1994;145:191-197.
6. Shelton GH, Linenberger ML. Hematologic abnormalities associated with retroviral infections in the cat. Semin Vet Med Surg (Small Anim) 1995;10:220-233.
7. Arjona A, Escolar E, Soto I, et al. Seroepidemiological survey of infection by feline leukemia virus and immunodeficiency virus in Madrid and correlation with some clinical aspects. J Clin Microbiol 2000;38:3448-3449.
8. Pedersen NC, Ho EN, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
9. Bendinelli M, Pistello M, Lombardi S, et al. Feline immunodeficiency virus: An interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995;8:87-112.
10. Adolf GR. Human Interferon omega-A review. Mult Scler 1995;1:S44-S47.
11. Tompkins MB, Cummins JM. Response of feline leukemia virus-induced noregenerative anemia to oral administration of an interferon-containing preparation. Feline Pract 1982;12:6-15.
12. Steed VP. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract 1987;17:24-30.
13. Cummins JM, Tompkins MB, Olsen RG, et al. Oral use of human alpha interferon in cats. J Biol Response Modif 1988;7:513-523.
14. Weiss RC, Cummins JM, Richards AB. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 1991;199:1477-1481.
15. Zeidner NS, Myles MH, Mathiason-Dubard CK, et al. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 1990;34:1749-1756.
16. Kociba GJ, Garg RC, Khan KNM, et al. Effects of orally administered interferon-α on the pathogenesis of feline leukaemia virus-induced erythroid aplasia. Comp Hematol Int 1995;5:79-83.
17. McCaw DL, Boon GD, Jergens AE, et al. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 2001;37:356-363.
18. Ueda Y, Sakurai T, Yanai A. Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J Vet Med Sci 1993;55:251-258.
19. Adolf GR, Maurer-Fogy I, Kalsner I, Cantell K. Purification and characterization of natural human interferon col. Two alternative cleavage sites for the signal peptidase. J Biol Chem 1990;265:9290-9295.
20. Truyen U, Blewaska S, Schultheiss U. Investigation of antiviral activity of interferon-omega (IFN-ω) against selected viruses from dog and cat [German]. Praktischer Tierarzt 2002;83:862-865.
21. Mochizuki M, Nakatani H, Yoshida M. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet Microbiol 1994;39:145-152.
22. Priosoeryanto BP, Tateyama S, Yamaguchi R, Uchida K. Anti-proliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro. Can J Vet Res 1995;59:67-69.
23. Tateyama S, Priosoeryanto BP, Yamaguchi R, Uchida K. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res Vet Sci 1995;59:275-277.
24. Minagawa T, Ishiwata K, Kajimoto T. Feline interferon-ω treatment on canine parvovirus infection. Vet Microbiol 1999;69:51-53.
25. Martin V, Najbar W, Gueguen S, et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 2002;89:115-127.
26. De Mari K, Maynard L, Eun HM, Lebreux B. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 2003;152:105-108.